The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy

Brachytherapy

Volumn 2, Issue 1, 2003, Pages 26-31

  Potters, Louis ^a   Huang, David ^a   Fearn, Paul ^a   Kattan, Michael W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; Nomogram; Prostate neoplasm; PSA

Indexed keywords

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE;

EID: 0142258750     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1538-4721(03)00004-7     Document Type: Article

References (15)

1. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;31-40.
2. Cha C.M., Potters L., Ashley R., et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys. 45:1999;391-395.
3. Blasko J., Grimm P., Sylvester J., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 46:2000;839-850.
4. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
5. Fleming I., Cooper J.S., Henson D.E., et al. AJCC cancer staging manual. 5th ed:1997;Lippincott-Raven, Philadelphia.
6. Potters L., Cha C., Oshinsky G., et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 5:1999;301-306.
7. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 22:1995;209-234.
8. Beyer D., Nath R., Butler W., et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;273-275.
9. Kattan M.W., Fearn P.A., Leibel S., et al. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 48:2000;1469-1474.
10. Cox D.R., Abadir R. Regression models and life tables. J R Stat Soc B. 34:1972;187-220.
11. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
12. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 12:2002;81-94.
13. Ling C.C. Permanent implants using Au-198, Pd-103 and I-125: Radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys. 23:1992;81-87.
14. Gelblum D., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 45:1999;59-67.
15. Wallner K., Merrick G., True L., et al. I-125 versus Pd-103 for low-risk prostate cancer: Morbidity outcomes from a prospective randomized multicenter trial. Cancer J. 8:2002;67-73.